Qiagen and Eppendorf form alliance
Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.
In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.
Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.
CSIRO announces 300+ job cuts as part of restructure
CSIRO will need to reduce roles in its Research Units by 300–350 full-time equivalent staff...
Synchron raises $305m to advance brain–computer interfaces
Synchron's Stentrode BCI platform is billed as the world's first endovascular...
Air quality expert wins 2025 PM's Prize for Science
Distinguished Professor Lidia Morawska's work in the study of air quality provided vital...

